P. Roach

发表

Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24‐h standardized test‐meal period in patients with Type 2 diabetes

P. Roach, P. Roach, J. Malone, 2006, Diabetic medicine : a journal of the British Diabetic Association.

New Insulin Analogues and Routes of Delivery

P. Roach, Paris Roach, 2008, Clinical pharmacokinetics.

Project RedCar: Cardiovascular Disease Risk Communication for People With Type 2 Diabetes Combining the Power of Electronic Health Records and Computer-Based Multimedia Technology

Melissa H. Cantrell, D. Marrero, C. Saha, 2010, Diabetes Spectrum.

Better systems, not guidelines, for glucose monitoring

P. Roach, 2004, BMJ : British Medical Journal.

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures

P. Roach, J. Woodworth, 2002, Clinical pharmacokinetics.

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.

M. Trautmann, J. Anderson, P. Roach, 1999, Clinical therapeutics.

EXTENSIVE PERSONAL EXPERIENCE Plasma Proinsulin-Like Component in Insulinoma: A %-Year Experience

J. Norton, J. Doppman, D. Fraker, 1995 .

Humalog® Mix50™ before carbohydrate‐rich meals in type 2 diabetes mellitus

P. Roach, B. Campaigne, P. Roach, 2003, Diabetes, obesity & metabolism.

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

A. Tiengo, A. Consoli, B. Charbonnel, 2004, Clinical therapeutics.

Nighttime Insulin Kinetics and Glycemic Control in Type 1 Diabetes Patients Following Administration of an Intermediate-Acting Lispro Preparation

R. Heine, W. Devillé, P. Roach, 1997, Diabetes Care.

Basal activity profiles of NPH and [Nɛ-palmitoyl Lys (B29)] human insulins in subjects with IDDM

L. Vignati, R. DiMarchi, R. Chance, 1998, Diabetologia.

A Novel Human Insulin Receptor Gene Mutation Uniquely Inhibits Insulin Binding Without Impairing Posttranslational Processing

D. Accili, Simeon I. Taylor, P. Formisano, 1994, Diabetes.

Good diabetes care: more than cheap meds.

D. Marrero, R. Ackermann, P. Roach, 2004, Medical care.

Improved glucose control following administration of a 75% insulin lispro/25% NPL mixture in patients with type 1 diabetes

P. Roach, J. Woodworth, U. Gudat, 2000 .

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

P. Roach, V. Arora, L. Yue, 1999, Diabetes care.

IMPROVED GLYCAEMIC CONTROL WITH THE USE OF SELF‐PREPARED MIXTURES OF INSULIN LISPRO AND INSULIN LISPRO PROTAMINE SUSPENSION IN PATIENTS WITH TYPES 1 AND 2 DIABETES

P. Roach, T. Strack, V. Arora, 2001, International journal of clinical practice.

The 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) score and diabetes risk in the Diabetes Prevention Program Outcomes Study (DPPOS)

Michael S. Reidy, Shawn S. Stephens, Bartholomew E. Clark, 2022, BMC Nutrition.

Plasma proinsulin-like component in insulinoma: a 25-year experience.

J. Norton, J. Doppman, D. Fraker, 1995, The Journal of clinical endocrinology and metabolism.

Association of Metformin With the Development of Age-Related Macular Degeneration.

Michael S. Reidy, Shawn S. Stephens, Jeong W. Pak, 2022, JAMA ophthalmology.

The Effect of Interventions to Prevent Type 2 Diabetes on the Development of Diabetic Retinopathy: The DPP/DPPOS Experience

Michael S. Reidy, Shawn S. Stephens, Jeong W. Pak, 2022, Diabetes Care.

Is type 2 diabetes reversible?

P. Roach, 2016, Diabetes forecast.

Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program

Michael S. Reidy, Bartholomew E. Clark, Denise R. Anderson, 2012, PLoS genetics.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

A Critical Dialogue: Communicating with Type 2 Diabetes Patients about Cardiovascular Risk

D. Marrero, P. Roach, 2005, Vascular health and risk management.

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

L. Heinemann, T. Heise, C. Weyer, 1998, Diabetes Care.

Sonography of gallbladder abnormalities in acromegaly patients following octreotide and ursodiol therapy: Incidence and time course

T. Shawker, M. Bradford, M. Skarulis, 1998, Journal of clinical ultrasound : JCU.

A prospective examination of octreotide‐induced gall‐bladder changes in acromegaly

T. Shawker, P. Gorden, R. Arakaki, 1992, Clinical Endocrinology.

Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin

P. Roach, P. Skierczynski, 2015, Diabetes Care.

Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH

Michael S. Reidy, Tanya M. Teslovich, Anne W. Ndungu, 2023, Diabetologia.

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

M. Cavaghan, P. Roach, R. Brunelle, 2009, Clinical therapeutics.

A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes

P. Roach, B. Cerimele, J. Woodworth, 2003, Diabetic medicine : a journal of the British Diabetic Association.

Listening to patients' voices: linguistic indicators related to diabetes self-management.

Marta Antón, U. Connor, P. Roach, 2013, Communication & medicine.